Respiratory Syncytial Virus Antibody (2F7): sc-101362

Respiratory Syncytial Virus Antibody (2F7) is a mouse monoclonal IgG1 antibody that detects the Respiratory Syncytial Virus protein of Respiratory Syncytial Virus origin by western blotting (WB), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-Respiratory Syncytial Virus antibody (2F7) is available as the non-conjugated format. Respiratory Syncytial Virus (RSV) is a significant pathogen responsible for severe respiratory illness, particularly in infants and young children who have not been vaccinated or treated. RSV is characterized as a negative-sense, enveloped RNA virus, with virions averaging between 120 and 300 nm in diameter. A critical aspect of RSV′s pathogenicity lies in its fusion protein, which facilitates the merging of viral and host cell membranes, allowing for viral entry and the formation of syncytia—multi-nucleated giant cells that can disrupt normal tissue function. Additionally, the matrix protein of RSV plays a vital role in the viral life cycle, not only aiding in viral assembly but also exhibiting the ability to traffic into and out of the nucleus at specific stages of infection. This nuclear trafficking is crucial as it may influence viral transcription and replication, thereby contributing to the virus′s ability to evade host immune responses and establish infection.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Respiratory Syncytial Virus Antibody (2F7) References:

1. Respiratory syncytial virus: pervasive yet evasive.  |  Weir, E. and Fisman, DN. 2004. CMAJ. 170: 191. PMID: 14734430
2. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.  |  Sastre, P., et al. 2004. Vaccine. 23: 435-43. PMID: 15530691
3. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.  |  Belshe, RB., et al. 2004. J Infect Dis. 190: 2096-103. PMID: 15551207
4. The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence.  |  Brock, SC., et al. 2005. J Virol. 79: 12528-35. PMID: 16160180
5. Arrhythmias associated with respiratory syncytial virus infection.  |  Playfor, SD. and Khader, A. 2005. Paediatr Anaesth. 15: 1016-8. PMID: 16238569
6. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.  |  Cilla, G., et al. 2006. Epidemiol Infect. 134: 506-13. PMID: 16638164
7. Central role of the respiratory syncytial virus matrix protein in infection.  |  Ghildyal, R., et al. 2006. FEMS Microbiol Rev. 30: 692-705. PMID: 16911040
8. Isolation of respiratory syncytial virus from nasopharyngeal aspirates stored at 20 degrees C from one to fifteen months after collection.  |  Nunes, IF. and Moura, FE. 2006. Mem Inst Oswaldo Cruz. 101: 451-3. PMID: 16951818
9. Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.  |  Becker, Y. 2006. Virus Genes. 33: 253-64. PMID: 16972041
10. Diagnosing and treating respiratory syncytial virus bronchiolitis.  |  Napierkowski, DB. 2016. Nurse Pract. 41: 1-4. PMID: 27552683
11. Vaccination strategies against respiratory syncytial virus.  |  Yamin, D., et al. 2016. Proc Natl Acad Sci U S A. 113: 13239-13244. PMID: 27799521
12. Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis.  |  Pillet, S., et al. 2024. Lancet Infect Dis. 24: 1192-1194. PMID: 39395423

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Respiratory Syncytial Virus Antibody (2F7) has 11 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Respiratory Syncytial Virus Antibody (2F7) Specifications

Alternate Product Name: Respiratory Syncytial Virus

Product Clone Name: 2F7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: Respiratory Syncytial Virus

Epitope Species: respiratory syncytial virus

Product Reactivity/Detection: fusion proteins F0 and F1

Species Reactivity/Detection: Respiratory Syncytial Virus

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, ELISA

Vialing Information: Each vial contains 50 µg IgG₁ in 500 µl of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 11 citations in various scientific publications

Available Conjugates/Forms for Respiratory Syncytial Virus Antibody (2F7): N/A